All In Biotech

NDA 213687 · Ultragenyx Pharm INC

Dojolvi

Triheptanoin · Oral · Medium-chain Triglyceride

NovelOrphan

Last checked: Nov 20, 2026Latest source record: Oct 30, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Jun 30, 2020

Approved uses

1

Original approval plus efficacy supplements

Registered trials

32

2 Phase 3, 1 recruiting

FAERS reports

554

350 serious, 69 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 10, 2025.

DOJOLVI is indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD). DOJOLVI is a medium-chain triglyceride indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).

Mechanism: Triheptanoin is a medium-chain triglyceride consisting of three odd-chain 7-carbon length fatty acids (heptanoate) that provide a source of calories and fatty acids to bypass the long-chain FAOD enzyme deficiencies for energy production and replacement.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 30, 2020 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelLetterReview
1 products under this application
  • DOJOLVI · TRIHEPTANOIN 100% w/w · LIQUID, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Triheptanoin" as an intervention, any sponsor and status, largest first.

All 32 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • vomiting88
  • diarrhoea77
  • rhabdomyolysis56
  • off label use53
  • abdominal pain upper44
  • abdominal discomfort36
  • blood creatine phosphokinase increased35
  • death33
  • nausea29
  • illness25
  • gastrointestinal disorder24
  • hospitalisation24

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202027
202190
2022117
2023114
202499
202567
202640

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Dojolvi (TriHEPtanoin)

2024 spending

$2.9M

Beneficiaries

19

140 claims

Per beneficiary

$151,602

$11.34 per unit

View as table
YearSpending
2020$0
2021$1,425,380
2022$2,240,768
2023$2,635,754
2024$2,880,438

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 22 on PubMed

Sponsor: Ultragenyx Pharm INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.